Timber Pharmaceuticals Inc. [AMEX: TMBR] loss -6.07% on the last trading session, reaching $2.01 price per share at the time. The company report on March 24, 2021 that Timber Pharmaceuticals Provides Business Update and Announces Year End 2020 Financial Results.
50% of patients in the Phase 2b CONTROL study have now been randomized despite COVID-19 disruptions in the trial marketplace.
Timber Pharmaceuticals Inc. represents 18.89 million in outstanding shares, while the company has a total market value of $23.96 million with the latest information. TMBR stock price has been found in the range of $1.92 to $2.18.
If compared to the average trading volume of 11.27M shares, TMBR reached a trading volume of 3529465 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Timber Pharmaceuticals Inc. [TMBR]:
The Average True Range (ATR) for Timber Pharmaceuticals Inc. is set at 0.46, with the Price to Sales ratio for TMBR stock in the period of the last 12 months amounting to 59.90.
Trading performance analysis for TMBR stock
Timber Pharmaceuticals Inc. [TMBR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.22. With this latest performance, TMBR shares gained by 6.91% in over the last four-week period, additionally plugging by 111.94% over the last 6 months – not to mention a drop of -45.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TMBR stock in for the last two-week period is set at 48.80, with the RSI for the last a single of trading hit 45.79, and the three-weeks RSI is set at 50.48 for Timber Pharmaceuticals Inc. [TMBR]. The present Moving Average for the last 50 days of trading for this stock 1.79, while it was recorded at 2.20 for the last single week of trading, and 1.50 for the last 200 days.
Timber Pharmaceuticals Inc. [TMBR]: A deeper dive into fundamental analysis
Timber Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.00.
Timber Pharmaceuticals Inc. [TMBR]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Timber Pharmaceuticals Inc. posted -2.64/share EPS, while the average EPS was predicted by analysts to be reported at -4.02/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 34.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TMBR.
An analysis of insider ownership at Timber Pharmaceuticals Inc. [TMBR]
There are presently around $0 million, or 10.40% of TMBR stock, in the hands of institutional investors. The top three institutional holders of TMBR stocks are: BRIDGEWAY CAPITAL MANAGEMENT, LLC with ownership of 158,300, which is approximately 0% of the company’s market cap and around 46.72% of the total institutional ownership; TWO SIGMA SECURITIES, LLC, holding 17,578 shares of the stock with an approximate value of $35000.0 in TMBR stocks shares; and UBS GROUP AG, currently with $26000.0 in TMBR stock with ownership of nearly 258.409% of the company’s market capitalization.
7 institutional holders increased their position in Timber Pharmaceuticals Inc. [AMEX:TMBR] by around 30,195 shares. Additionally, 3 investors decreased positions by around 26,592 shares, while 3 investors held positions by with 135,391 shares. The mentioned changes placed institutional holdings at 192,178 shares, according to the latest SEC report filing. TMBR stock had 5 new institutional investments in for a total of 17,838 shares, while 3 institutional investors sold positions of 26,592 shares during the same period.